

# Eliseo Pascual

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3859133/publications.pdf>

Version: 2024-02-01

88  
papers

6,741  
citations

147801

31  
h-index

64796

79  
g-index

95  
all docs

95  
docs citations

95  
times ranked

4459  
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 updated EULAR evidence-based recommendations for the management of gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 29-42.	0.9	1,096
2	EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCSIT). <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1312-1324.	0.9	1,079
3	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005, 52, 1766-1772.	6.7	612
4	European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 563-570.	0.9	418
5	Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1976, 6, 192-199.	2.0	303
6	Gout: why is this curable disease so seldom cured?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1765-1770.	0.9	228
7	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 31-38.	0.9	225
8	“Crystal Clear” Sonographic Assessment of Gout and Calcium Pyrophosphate Deposition Disease. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 36, 197-202.	3.4	202
9	Synovial Fluid Analysis for Diagnosis of Intercritical Gout. <i>Annals of Internal Medicine</i> , 1999, 131, 756-759.	3.9	200
10	EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 571-575.	0.9	193
11	Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. <i>Arthritis and Rheumatism</i> , 1991, 34, 141-145.	6.7	172
12	Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 654-661.	8.0	169
13	Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1522-1528.	0.9	155
14	Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1056-1058.	0.9	135
15	Analysis for crystals in synovial fluid: training of the analysts results in high consistency. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 612-615.	0.9	106
16	Most calcium pyrophosphate crystals appear as non-birefringent. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 582-584.	0.9	94
17	Synovial fluid analysis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 371-386.	3.3	89
18	Understanding How the Diagnostic Delay of Spondyloarthritis Differs Between Women and Men: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2017, 44, 174-183.	2.0	85

#	ARTICLE	IF	CITATIONS
19	Mechanisms of crystal formation in gout—a structural approach. <i>Nature Reviews Rheumatology</i> , 2015, 11, 725-730.	8.0	79
20	Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1531-1539.	5.6	74
21	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
22	Why is gout so poorly managed?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1269-1270.	0.9	72
23	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
24	Synovial fluid analysis for crystals. <i>Current Opinion in Rheumatology</i> , 2011, 23, 161-169.	4.3	62
25	Mononuclear cells in human synovial fluid. Identification of lymphoblasts in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1976, 19, 743-748.	6.7	47
26	Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid. <i>Arthritis and Rheumatism</i> , 1975, 18, 603-612.	6.7	43
27	Synovial Fat Necrosis Associated with Ischemic Pancreatic Disease. <i>Arthritis and Rheumatism</i> , 1979, 22, 547-553.	6.7	41
28	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 349-355.	0.9	41
29	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.9	38
30	Febuxostat. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 191-192.	46.4	36
31	Therapeutic advances in gout. <i>Current Opinion in Rheumatology</i> , 2007, 19, 122-127.	4.3	34
32	Gout: The mechanism of urate crystal nucleation and growth. A hypothesis based in facts. <i>Joint Bone Spine</i> , 2013, 80, 1-4.	1.6	27
33	Gout: optimizing treatment to achieve a disease cure. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 135-144.	2.5	27
34	Gout. <i>Current Opinion in Rheumatology</i> , 2004, 16, 282-286.	4.3	24
35	Methotrexate Is an Option for Patients With Refractory Calcium Pyrophosphate Crystal Arthritis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 234-236.	0.9	24
36	Therapy for CPPD: Options and Evidence. <i>Current Rheumatology Reports</i> , 2018, 20, 31.	4.7	24

#	ARTICLE	IF	CITATIONS
37	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
38	Gout treatment: should we aim for rapid crystal dissolution?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 635-637.	0.9	22
39	Challenges to conquer from the gender perspective in medicine: The case of spondyloarthritis. <i>PLoS ONE</i> , 2018, 13, e0205751.	2.5	20
40	Hyperuricemia and gout. <i>Current Opinion in Rheumatology</i> , 1994, 6, 454.	4.3	18
41	Severe gout: Strategies and innovations for effective management. <i>Joint Bone Spine</i> , 2017, 84, 541-546.	1.6	18
42	Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan. <i>Pain</i> , 2018, 159, 739-748.	4.2	18
43	Gout update: from lab to the clinic and back. <i>Current Opinion in Rheumatology</i> , 2000, 12, 213-218.	4.3	17
44	Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 155-155.	0.9	14
45	Acute Hip Monoarthritis in a Patient Treated With Isotretinoin. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 105-106.	0.9	13
46	Criteria for Gout Diagnosis?. <i>Journal of Rheumatology</i> , 2013, 40, 356-358.	2.0	12
47	Most needle-shaped calcium pyrophosphate crystals lack birefringence. <i>Rheumatology</i> , 2019, 58, 1095-1098.	1.9	12
48	Managing Gout in the Patient with Renal Impairment. <i>Drugs and Aging</i> , 2018, 35, 263-273.	2.7	10
49	Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2563-2564.	5.6	9
50	Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report. <i>Joint Bone Spine</i> , 2018, 85, 377-378.	1.6	9
51	Acute arthritis following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 661-661.	5.0	9
52	Gout: new advances in the diagnosis and management of an old disease. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 203-220.	0.3	8
53	Current advances in therapies for calcium pyrophosphate crystal arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 140-144.	4.3	8
54	Manifestations articulaires de l'arthrose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006, 73, 362-368.	0.0	7

#	ARTICLE	IF	CITATIONS
55	Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e2-e2.	0.9	7
56	Impaired Trunk Posture in Women With Fibromyalgia. <i>Spine</i> , 2018, 43, 1536-1542.	2.0	7
57	Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study. <i>Rheumatology</i> , 2019, 58, 1104-1105.	1.9	7
58	Reviewing Disease Activity Indices in Spondyloarthritis From the Sex Perspective: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021, 48, 1395-1404.	2.0	7
59	An Unusual Tophus. <i>New England Journal of Medicine</i> , 2015, 372, e6.	27.0	6
60	Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?. <i>Arthritis Research and Therapy</i> , 2015, 17, 89.	3.5	6
61	Sex and Gender Interactions in the Lives of Patients with Spondyloarthritis in Spain: A Quantitative-qualitative Study. <i>Journal of Rheumatology</i> , 2017, 44, 1429-1435.	2.0	6
62	Normal Initial Magnetic Resonance Imaging in Aseptic Bone Necrosis of the Knee. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 101-104.	0.9	5
63	Progresses in the imaging of calcium pyrophosphate crystal disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 140-145.	4.3	5
64	Editorial: Decreasing Crystal-Induced Consternation: New Methods of Crystal Identification. <i>Arthritis and Rheumatology</i> , 2016, 68, 1574-1577.	5.6	4
65	Mixed Crystal Disease: A Tale of 2 Crystals. <i>Journal of Rheumatology</i> , 2020, 47, 1158-1159.	2.0	4
66	Calcium pyrophosphate crystal deposition. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 677-688.	0.3	3
67	Is Remission a Valid Target for Gout?. <i>Journal of Rheumatology</i> , 2020, 47, 4-5.	2.0	3
68	International position paper on febuxostat. <i>Clinical Rheumatology</i> , 2010, 29, 835.	2.2	3
69	Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. <i>Joint Bone Spine</i> , 2022, 89, 105423.	1.6	3
70	Infectious Arthritis of a Lumbar Facet Joint. <i>Journal of Clinical Rheumatology</i> , 1999, 5, 22-24.	0.9	2
71	Back Pain Due to Lumbar Gouty Flare – A Prospective Diagnosis. <i>Journal of Rheumatology</i> , 2013, 40, 1459-1460.	2.0	2
72	Rapid crystal dissolution in gout: is it feasible and advisable?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 395-401.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. <i>Rheumatology</i> , 2015, 54, 1328-1329.	1.9	2
74	SUA levels should not be maintained <math>\leq 3</math> mg/dL for several years. Response to EULAR gout treatment guidelines by Richette et al: uric acid and neurocognition by Singh et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e21-e21.	0.9	2
75	Synovial Fluid Crystal Analysis. , 2012, , 20-34.		1
76	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters. <i>American Journal of Medicine</i> , 2015, 128, e41-e42.	1.5	1
77	Gout mimicking rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, e28.	3.4	1
78	Clinical Images: Hematoidin in Synovial Fluid. <i>Arthritis and Rheumatology</i> , 2017, 69, 836-836.	5.6	1
79	Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register. <i>Rheumatology International</i> , 2017, 37, 941-948.	3.0	1
80	SAPHO Presenting with a Lesion in the Symphysis Pubis. <i>Journal of Clinical Rheumatology</i> , 1998, 4, 28-31.	0.9	0
81	Diagnosis of Intercritical Gout. <i>Annals of Internal Medicine</i> , 2000, 132, 843.	3.9	0
82	Artrocentesis de la primera articulaci3n metatarsofal3ngica. <i>Seminarios De La Fundaci3n Espa3ola De Reumatolog3a</i> , 2007, 8, 127-129.	0.1	0
83	Gout and the heart: beyond comorbidities. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 329-334.	0.3	0
84	Urate crystals and inflammation. Cardiovascular impact of gout. <i>International Journal of Cardiology</i> , 2018, 271, 295.	1.7	0
85	Crystal Analysis in Synovial Fluid. , 2019, , 47-58.		0
86	Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 208-212.	0.9	0
87	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. <i>Reumatolog3a Cl3nica</i> , 2022, 18, 129-130.	0.5	0
88	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2022, 18, 129-130.	0.3	0